You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 1 (abstract P166). | Journal for ImmunoTherapy of Cancer

Fig. 1 (abstract P166).

From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One

Fig. 1 (abstract P166).

The H3.3K27M peptide is detectable by LC-MS/MS in the HLA-class I immunopeptidome of glioma cells bearing the H3.3K27M mutation. HLA-class I peptides were biochemically purified from U87H3.3K27M glioma cells and analyzed by LC-MS/MS with a synthetic heavy version of the H3.3K27M peptide as the reference. A. U87H3.3K27M HLA-class I immunopeptidome shows two co-eluting isotope patterns corresponding to the target m/z and mass difference of the oxidized forms of the heavy and the endogenous H3.3K27M peptides. B. Fragmentation spectrum of the heavy peak, showing identification of the oxidized heavy H3.3K27M peptide. C. Zoom-in of the light isotope pattern shows m/z values and distances between peaks as expected from the endogenous H3.3K27M peptide.

Back to article page